View examples of how we address the unique need of every research question to deliver innovative, multidimensional solutions to convey the value of healthcare innovations. Download our posters from recent conferences.

23rd International AIDS Conference PosterLink
Comparative Efficacy and Safety of a Combination Therapy of Dolutegravir and Lamivudine VS 3-Drug Antiretroviral Regimens in Treatment-Naive HIV-1 Infected Patients at 96 Weeks: A Systematic Review and Network Meta-AnalysisDownload
ISPOR 2020 PostersLink
Humanistic Burden Associated with Depression and Anxiety Among Adults with Non-Communicable Chronic Diseases (NCCDs) in the United StatesDownload
Budget Impact Analysis of Introduction of Rituximab Biosimilar in the United States from a Payer PerspectiveDownload
Comparison of Treatment Adherence And Persistence with Edoxaban Versus Apixaban, Dabigatran, Rivaroxaban, and Vitamin K Antagonist in Non-Valvular Atrial Fibrillation Patients in Germany: A Propensity Matched Cohort StudyDownload
Budget Impact Analysis of Introduction of Bevacizumab Biosimilar in the United States from a Payer PerspectiveDownload
Budget Impact Analysis of Introduction of IV Trastuzumab Biosimilar (Trastuzumab-qyyp) from Buyer and Payer Perspectives in FranceDownload
Real-World Economic and Clinical Outcomes Associated with Current Hemostatic Matrix Use in Spinal SurgeryDownload
Real-World Economic and Clinical Outcomes Associated with Current Hemostatic Matrix Use in Cardiovascular SurgeryDownload
ISPOR Europe SymposiumLink
SURVIVAL MODELLING: TRENDS AND INNOVATIONSDownload
ISPOR HEOR TheaterLink
COMMUNICATING VALUE TO DECISION-MAKERS: WHAT’S YOUR PROGNOSIS?Download
ISPOR Europe 2019 PostersLink
COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALYDownload
COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAINDownload
COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLANDDownload
UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMADownload
STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMADownload
COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECEDownload
COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCEDownload
USING MACHINE LEARNING FOR EFFICIENCY IMPROVEMENTS IN SYSTEMATIC LITERATURE REVIEWS OF CLINICAL EFFICACY AND SAFETYDownload
BAYESIAN MODEL AVERAGING FOR EXTRAPOLATING SURVIVAL: A PAN-TUMOR PERSPECTIVE ON NIVOLUMAB AND IPILIMUMABDownload
MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALSDownload
COMPARISON OF TIME TO REIMBURSEMENT RECOMMENDATIONS OF (ORPHAN-) ONCOLOGY DRUGS IN EUROPEDownload
MAXIMUM LIKELIHOOD ESTIMATION TO QUANTIFY THE IMPACT OF TREATMENT RESPONSE ON SURVIVAL OUTCOMESDownload
BALANCING GLOBAL HTA REQUIREMENTS FOR LITERATURE REVIEWS ACROSS EUROPE, NORTH AMERICA, AND ASIADownload
IMPROVING THE ACCURACY AND REDUCING UNCERTAINTY OF PROBABILISTIC PARTITIONED SURVIVAL ANALYSES, BY CONSIDERING THE RELATIONSHIP BETWEEN PFS AND OSDownload
AMCP Nexus 2019Link
CHARACTERISTICS, SYSTEMIC TREATMENTS AND OUTCOMES IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A SYSTEMATIC LITERATURE REVIEWDownload